Hepalink Shifts To Drug Development With Resverlogix Deal

17 Jul 2015

• By Ying Huang

China's Shenzhen Hepalink Pharmaceutical, a publicly traded company that claims to be one of the largest makers of heparin in the world, has ambitions to build up its research and development activities for innovative drugs and is making substantial investments in overseas companies to achieve them.

SHANGHAI - Shenzhen Hepalink Pharmaceutical Co. Ltd. has in-licensed RVX-208 (apabetalone), a BET (bromodomain and extra-terminal) inhibitor, for all indications from Canada’s Resverlogix Corp. The deal will also involve an equity investment of CAD50 million ($38.7 million) in Resverlogix.

This move sees Hepalink’s strategic development plan of switching from a heparin sodium active pharmaceutical ingredient supplier to an innovative...